Physician profile
William H Whaley
NPI 1679551261
$1,248.25
in general payments reported to CMS, 2019-2025
20 companies · $562 in 2025
The $562 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.70 · 2021: $43.72 · 2022: $60.02 · 2023: $101 · 2024: $387 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,033 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,032.79 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $241.46 | 2022-2025 | Rybrevant, Carvykti, Erleada |
| Astrazeneca Pharmaceuticals LP | $158.27 | 2019-2024 | Lynparza, Enhertu |
| Alnylam Pharmaceuticals INC. | $145.20 | 2025 | Amvuttra |
| Glaxosmithkline, LLC. | $125.00 | 2024 | Ojjaara |
| Pfizer INC. | $112.21 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $67.08 | 2025 | Keytruda |
| Novartis Pharmaceuticals Corporation | $46.98 | 2023-2025 | |
| Abbvie INC. | $44.11 | 2024-2025 | |
| Exelixis INC. | $41.20 | 2022 | |
| Astellas Pharma US INC | $40.28 | 2023-2024 | Padcev |
| Tersera Therapeutics LLC | $34.72 | 2025 | Zoladex |
| Gilead Sciences, INC. | $34.37 | 2021-2024 | |
| Foundation Medicine, INC. | $27.21 | 2023 | Foundationone Liquid Cdx |
| Eisai INC. | $23.14 | 2024 | |
| Genentech USA, INC. | $20.07 | 2024 | Lunsumio, Columvi |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $19.70 | 2025 | Vanflyta |
| Beigene USA, INC. | $17.75 | 2024 | Tevimbra |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Array Biopharma INC | $16.46 | 2025 | Tukysa, Braftovi, Mektovi |
| Puma Biotechnology, INC. | $16.02 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Whaley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.